eNewsletter—Identifying and Correcting Disparities in Cancer Care for Minority Populations: The Importance of Participation by Non-Oncologists
A recap of key points presented during the prIME Oncology satellite symposium held on August 1, 2017 in conjunction with the National Medical Association (NMA) Annual Convention & Scientific Assembly in Philadelphia, Pennsylvania. The eNewsletter’s content and the views expressed therein are those of the presenters and not of NMA.
- Racial Disparities in Prostate Cancer in 2017
- Breast Cancer in African Americans: Opportunities for Reducing Disparities
- Cervical Cancer Update 2017
- Lynch Syndrome: Hereditary Cancer Risk in Minority Populations
This educational activity is specifically designed to meet the needs of internists, general practitioners, surgeons, obstetricians/gynecologists, urologists, gastroenterologists, and other healthcare providers.
After successful completion of this educational activity, participants should be able to:
- Employ current evidence-based best practices regarding the utilization of diagnostic tools for patients with prostate cancer
- Assess the implications of disparities on the diagnosis of patients with breast cancer and utilize strategies to overcome these disparities to improve outcomes
- Integrate recent data regarding the potential influence of racial disparities on the diagnosis and, ultimately, clinical outcomes of patients with cervical cancer
- Evaluate the implications of disparities on screening and diagnosis for patients with Lynch syndrome
This activity is provided by prIME Oncology.
prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.
prIME Oncology designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Each newsletter may provide the following credits:
- Prostate Cancer: 0.25
- Breast Cancer: 0.25
- Cervical Cancer: 0.25
- Lynch Syndrome: 0.25
September 30, 2017
September 30, 2018
This educational activity is supported by grants from Astellas; Lilly USA, LLC; and Merck and Co, Inc.